Impedimed Ltd has released a press release.
FDA Grants Breakthrough Device Designation for Renal Failure
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Earlier from Impedimed
- Official Release of SOZO Version 4.0 Software
- ACC Abstract Demonstrates Potential of SOZO in Heart Failure
- Appendix 4C - Quarter ended 31 March 2021
- FDA Clearance for SOZO Heart Failure Index
- SOZO Clinical Utility in Heart Failure Published
Later from Impedimed
- Receipt of $1.8 Million R&D Tax Incentive Refund
- HFSA Abstracts Demonstrate Utility of SOZO for HF Patients
- SOZO Heart Failure Program Initiated at AdvocateAuroraHealth
- New Corporate Oncology Account with Icon Group
- PREVENT Trial Successful, Statistically Significant Results
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed